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Abstract
Background: The high HIV prevalence in South Africa may potentially be shaping the local adverse drug reaction
(ADR) burden. We aimed to describe the prevalence and characteristics of serious ADRs at admission, and during
admission, to two South African children’s hospitals.
Methods: We reviewed the folders of children admitted over sequential 30-day periods in 2015 to the medical
wards and intensive care units of each hospital. We identified potential ADRs using a trigger tool developed for this
study. A multidisciplinary team assessed ADR causality, type, seriousness, and preventability through consensus
discussion. We used multivariate logistic regression to explore associations with serious ADRs.
Results: Among 1050 patients (median age 11 months, 56% male, 2.8% HIV-infected) with 1106 admissions we
found 40 serious ADRs (3.8 per 100 drug-exposed admissions), including 9/40 (23%) preventable serious ADRs, and
8/40 (20%) fatal or near-fatal serious ADRs. Antibacterials, corticosteroids, psycholeptics, immunosuppressants, and
antivirals were the most commonly implicated drug classes. Preterm neonates and children in middle childhood (6
to 11 years) were at increased risk of serious ADRs compared to infants (under 1 year) and term neonates: adjusted
odds ratio (aOR) 5.97 (95% confidence interval 1.30 to 27.3) and aOR 3.63 (1.24 to 10.6) respectively. Other risk
factors for serious ADRs were HIV infection (aOR 3.87 (1.14 to 13.2) versus HIV-negative) and increasing drug count
(aOR 1.08 (1.04 to 1.12) per additional drug).
Conclusions: Serious ADR prevalence in our survey was similar to the prevalence found elsewhere. In our setting,
serious ADRs were associated with HIV-infection and the antiviral drug class was one of the most commonly
implicated. Similar to other sub-Saharan African studies, a large proportion of serious ADRs were fatal or near-fatal.
Many serious ADRs were preventable.
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Background
Patient safety is of central importance to all fields of
medicine. However, in paediatric medicine, clinicians are
faced with the reality that pre-registration drug safety
data are often very limited, and that extrapolation from
adult drug safety data may be inappropriate in view of
children’s physiological development. As such, post-
marketing surveillance is critical in the ongoing safety
appraisal of drugs given to children [1].
South Africa was home to an estimated 280,000 chil-
dren living with HIV in 2017, of which an estimated 58%
were on antiretroviral treatment (ART) [2]. Despite this
high prevalence of HIV, and despite ART’s notorious
potential to cause adverse drug reactions (ADRs) and
drug-drug interactions, drug safety is a relatively under-
studied field in South Africa. Local paediatric drug safety
data could potentially contribute to clinical decision-
making and health programme policy-making.
Our main aim with this survey was to describe the
prevalence of serious ADRs in two paediatric hospitals
in South Africa, including the prevalence of serious
ADRs at the time of admission and the prevalence of
serious ADRs occurring during the admission. Further
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aims were to describe serious ADR manifestations and
the drugs implicated in serious ADRs, to describe the
preventability of serious ADRs, to describe the preva-
lence and manifestations of non-serious ADRs in this
setting, and to explore the influence of HIV on ADRs
occurring in this patient population.
Methods
Design and setting
We conducted this observational study through folder
review of data documented during routine clinical care
of patients at two hospitals in South Africa: Red Cross
War Memorial Children’s Hospital (RCWMCH), situ-
ated in Cape Town, Western Cape province, and Rahima
Moosa Mother and Child Hospital (RMMCH), situated
in Johannesburg, Gauteng province. We selected these
sites based on existing research collaborations. Both sites
have paediatric ART clinics.
At RCWMCH, we surveyed all patients admitted elec-
tively and non-electively over a 30-day period in April
and May 2015 to the general and specialist medical
wards, to high-care beds in the medical wards, to the
combined paediatric intensive care unit, and to the gen-
eral section (but not the rehydration section) of the
short-stay ward. We excluded admissions to surgical or
oncology wards if the entire stay was spent in the surgi-
cal and oncology wards, but included those portions of
surgical and oncology patients’ admissions spent in the
paediatric intensive care unit. The hospital provides lim-
ited neonatal services. Admission trends to RCWMCH
have previously been described [3]. At RMMCH, we sur-
veyed all patients admitted non-electively over a 30-day
period in June and July 2015 to the medical wards and
to the combined intensive care / high-care unit. Al-
though RMMCH provides neonatology services, we only
surveyed those neonates admitted to the intensive care /
high-care unit, and not those admitted to the postnatal
wards. Elective admissions to RMMCH, which were ex-
cluded from our survey, consisted mostly of children ad-
mitted as day patients for minor surgical procedures.
Sample size considerations
We calculated that a sample of 514 patients would detect
a prevalence of serious ADRs present at admission of 2.9%
(based on a previous systematic review [4]) with a 95%
confidence interval (CI) of 1.6 to 4.8%, using the exact CI
method of Clopper-Pearson [5]. Based on historic admis-
sion trends at the sites and specific wards included in the
survey, we were confident that we would survey at least
514 admissions during the planned study duration.
Study processes
We consulted hospital administrative records every
weekday during the 30-day survey period to identify all
new admissions. The survey team (a general practitioner
and a pharmacist) reviewed each patient’s clinical notes,
medication prescription charts, and laboratory results as
soon as possible after admission and approximately
every second day thereafter until the patient’s discharge
or death, or until study closure, seven days after the end
of the 30-day survey entry period. At the time of the pa-
tient’s discharge, the survey team specifically reviewed
the discharge summary prepared by the clinical team to
verify and augment data already collected. For patients
admitted to the RCWMCH short-stay ward, we con-
ducted folder reviews retrospectively approximately five
months following the admission, and not prospectively
as described above, as piloting showed it to be too
resource-intensive to survey admissions prospectively in
this ward.
We abstracted demographic and clinical data (includ-
ing medication histories) from all patients using elec-
tronic case report forms. The survey team identified
potential ADRs during the folder review with the help of
a trigger tool (Table 1, development described below).
For cases flagged by the trigger tool, we abstracted a
more detailed dataset, including relevant laboratory re-
sults, and details on the management and outcome of
the potential ADR. In a second stage of ADR identifica-
tion and assessment, a multidisciplinary team (the survey
team, together with a paediatrician, a paediatrician
highly experienced in neonatology, a clinical pharma-
cologist, and a clinical pharmacist) discussed flagged
cases’ abstracted data to reach consensus on causality
(thereby determining whether the potential ADR was ac-
tually an ADR), ADR type, seriousness, and preventabil-
ity, using definitions described below.
Definitions, classifications, and taxonomies
We defined ADRs according to the 2005 Aronson and
Ferner definition [6]. We performed causality assessment
according to the World Health Organization (WHO)-
Uppsala Monitoring Centre system for standardised case
causality assessment [7]. Those potential ADRs where
drug causation was assessed as certain, probable, or pos-
sible were counted as ADRs. We specifically did not
consider the following scenarios to be ADRs: intentional
drug overdose, poisoning by or ingestion of non-
medicinal products, poisoning by herbal or traditional
remedies, therapeutic failures, complications associated
with poor adherence, and medication errors which were
not associated with any harm. We codified ADRs to
‘preferred terms’ in version 17.1 of the Medical Diction-
ary for Regulatory Activities (MedDRA®, MedDRA
Maintenance and Support Services Organization,
McLean, VA, USA). We classified ADRs as preventable
if at least one of the Schumock and Thornton prevent-
ability questions [8] were answered affirmatively by the
Mouton et al. BMC Pediatrics            (2020) 20:3 Page 2 of 14
Table 1 Trigger list used to assist in identifying potential adverse drug reactions
Category Trigger





Digoxin immune fab (“Digibind”)
Protamine sulphate
Activated charcoal











Supratherapeutic drug concentration suggests a
potential ADR occurred
Digoxin > 1.5 nmol/L
Theophylline > 110 μmol/L
Lidocaine > 5 μg/L
Phenytoin > 80 μmol/L
Carbamazepine > 51 μmol/L
Phenobarbital > 172 μmol/L
Valproic acid > 700 μmol/L
Gentamicin or tobramycin peak > 10 mg/L or 24 h trough > 2mg/L
Amikacin peak > 30 mg/L or 24 h trough > 2mg/L
Vancomycin trough > 25mg/L or > 30 mg/L during continuous infusion
Any other drug concentration reported as supratherapeutic
Paracetamol concentration done (regardless of result)
Laboratory result (other than TDM) suggests a
potential ADR occurred
Partial thromboplastin time (PTT) > 100 s
International normalised ratio (INR) > 5
Anti-factor Xa≥ 1.5 IU/mL
Platelet count < 50 × 109/L
White cell count < 3 × 109/L
Haemoglobin < 8 g/dL
Pancytopaenia
Clostridium difficile positive stool after exposure to antibiotics
Creatinine rising to above-normal range
Hyponatraemia or Hypernatraemia
Potassium < 3.5 mmol/L, in the absence of diarrhoea
Potassium > 5.5 mmol/L
Alanine transaminase (ALT) > three times upper limit of normal (ULN = 40 IU/L) in the presence of
negative viral hepatitis screening test results
Bilirubin > two times upper limit of normal (ULN = 21 μmol/L); if in a neonate, the neonate
should also be on drugs
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multidisciplinary team. We classified ADRs in accord-
ance with the Rawlins and Thompson classification as
type A or type B [9]. We used this classification to de-
cide the level at which we conducted causality and pre-
ventability assessment in the event that multiple drugs
were implicated in the ADR, as described in a previous
paper by our group [10]. If multiple drug suspects were
implicated in a type A ADR, we assessed causality and
preventability based on the combined action of all the
drug suspects. If multiple drug suspects were implicated
in a type B ADR, we assessed causality and preventability
for each drug suspect–ADR pair separately. We cate-
gorised the seriousness of ADRs as per Temple [11], as
causing: (i) increased monitoring but no harm; (ii) tem-
porary harm, requiring treatment intervention; (iii) ini-
tial / prolonged hospitalization; (iv) permanent harm; (v)
near-death; or (vi) death. We defined serious ADRs as
those ADRs resulting in hospital admission, or prolong-
ing hospital admission, or causing permanent harm,
near-death, or death.
We recorded drugs by generic names only and codi-
fied these according to the World Health Organization’s
Anatomical Therapeutic Chemical Classification System
(ATC) [12]. We defined the total drug count as the
number of unique ATC codes to which the patient was
exposed over the 30-day period before the admission
and during their observed hospital stay. We similarly
calculated a background drug count (over the 30-day
period before the admission) and an in-hospital drug
count for each admission. When determining drug
counts, we excluded drugs applied topically to the skin,
eyes, ears, nose, throat, or mouth.
We categorised age according to National Institute of
Child Health and Human Development Pediatric
Table 1 Trigger list used to assist in identifying potential adverse drug reactions (Continued)
Category Trigger
Serum glucose < 3mmol/L, outside the perinatal period
Hyperlactataemia on antiretroviral therapy
Clinical event suggests a potential ADR occurred Angioedema or lip swelling
Rash or ulceration




Dystonia, ataxia, torticollis, dyskinesia
Retinopathy in premature infant on oxygen
Hearing disturbance or hearing loss
Seizure(s)
Oversedation, lethargy, falls






Nausea reported by parents / documented in file
Constipation
Biopsy of bone marrow, kidney, or liver
Withdrawal symptoms
Any other event suspected to be drug-related by doctor or nurse
Unexplained medication stop
Readmission to acute care unit within 14 days of discharge
Readmission to intensive care unit within 48 h of transfer or discharge
Require resuscitation in ward
Death
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Terminology as follows: preterm neonate, born before
37 completed weeks’ gestation; term neonate, from birth
to 27 days; infancy, 28 days to 12 months; toddler, 13
months to 24months; early childhood, 25 months to 5
years; middle childhood, 6 years to 11 years; early adoles-
cence, 12 years to 18 years [13]. We used the admission
weight to calculate a weight-for-age z-score using stan-
dards developed in the WHO Multicentre Growth Refer-
ence Study [14] for infants, toddlers, and children in
early childhood years. We abstracted HIV status as in-
fected, negative, or unknown, and perinatal HIV expos-
ure status in children < 18months old as exposed,
unexposed, or unknown. We combined HIV status and
perinatal HIV exposure into a single stratified variable as
follows: [1] HIV-infected; [2] HIV-negative, consisting of
children < 18months who were not perinatally exposed,
children ≥18months who were serologically negative,
and children ≥18 months in whom HIV testing was not
clinically indicated; and [3] an indeterminate group of
children < 18 months, who were or may have been peri-
natally exposed to HIV but whose HIV infection status
was not yet confirmed.
Trigger tool development
We conducted a literature review to identify previous
studies that used triggers to detect potential ADRs or
harm in children, or potential ADRs in adults. We com-
bined all the drug-related triggers from these various
tools. A multidisciplinary panel of seven experts (a clin-
ical pharmacist, a clinical pharmacologist, two paediatri-
cians, a paediatric HIV clinician, and two research
medical officers) then decided on the inclusion of each
trigger in a two-round modified Delphi method. In
round 1, each expert independently rated the inclusion
of the trigger on a 5-point Likert scale (5 = strongly
agree that the trigger should be included on the trigger
tool; 1 = strongly disagree that the trigger should be in-
cluded on the trigger tool). We calculated the median
score, first (Q1), and third (Q3) quartiles for each trig-
ger. We defined agreement to include each potential
trigger as a median score ≥ 4 and Q1 ≥ 4, and agreement
to exclude each potential trigger as a median score ≤ 2
and Q3 ≤ 2. Additionally, experts were asked to add po-
tential triggers to the list during round 1. In round 2, ex-
perts met to discuss triggers without agreement to
include or exclude, as well as all the potential triggers
added during round 1. Experts then re-scored, or in the
case of newly added triggers scored, these triggers inde-
pendently on the same scale. We again defined agree-
ment to include each potential trigger as a median
score ≥ 4 and Q1 ≥ 4. Triggers with agreement to include
in the first or second round were included in the final
trigger list.
Data management and statistical analysis
We entered data into a purpose-built Access 2013 data-
base (Microsoft Corporation, Redmond, WA). We ana-
lysed data using Stata 13.1 (Stata Corporation, College
Station, TX), including the macro igrowup_restricte-
d.ado (version 3.2.2, January 2011) [15] to calculate
weight-for-age z-scores.
We summarised continuous variables by means and
standard deviations, or by medians and interquartile ranges
(IQR), depending on their distribution. We explored associ-
ations between binary and categorical variables through
cross-tabulation and chi-square statistics, and we con-
ducted between-group comparisons of continuous variables
using the Wilcoxon rank-sum test or Student’s t test, de-
pending on the distribution. A P value of < 0.05 was taken
to indicate statistically significant difference.
We conducted multivariate analysis of associations
with serious ADR by constructing a logistic regression
model. We limited this model to children documented
to have been exposed to at least one drug before and /
or during their admission, and to first admissions only
in the event of multiple admissions per patient. Variables
which were selected a priori for inclusion in the model
as predictor variables were age category, sex, hospital
site, the summary HIV infection / exposure category de-
scribed above, and total drug count. In the subgroup of
patients for whom weight-for-age z-scores could be cal-
culated, we conducted an explorative analysis adding this
variable to the model.
Ethical issues
Our study received ethical approval from the Human Re-
search Ethics Committees of the University of Cape Town
(approval number 576/2011) and the University of the
Witwatersrand (clearance certificate number M140707).
We received permission to conduct the research from
both hospitals. We did not request individual patients’ or
caregivers’ consent, as this study was a non-interventional
review of medical records, and this was approved by the
ethics committees. We shared anonymised study findings
with the South African National Adverse Drug Event
Monitoring Centre, which collects spontaneous reports on
behalf of the national medicines regulator. Partial,
provisional results were shared at the 32nd International
Conference on Pharmacoepidemiology & Therapeutic
Risk Management and were published as an abstract [16].
Results
Trigger tool development
Our literature search yielded 31 articles. We compiled a
list of 110 triggers from 16 included studies (see Add-
itional file 1: Table S1). In round 1 of the modified Del-
phi method, we agreed to include 37 triggers and agreed
to exclude one. In round 2, 74 triggers (72 from round 1
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and two newly proposed triggers) were discussed. We
agreed to include a further 35; the final trigger list con-
sisted of 72 triggers (Table 1). Seventeen triggers refer to
drugs used as antidotes (e.g. naloxone) or in the man-
agement of adverse events, 12 describe laboratory evi-
dence of high drug concentrations, 16 refer to other
abnormal laboratory values, and 27 relate to clinical
events suggesting adverse drug events (e.g. unexplained
medication stop.)
Sample description
There were 1050 patients and 1106 admissions (range
one to four admissions per patient). Patient characteris-
tics are described in Table 2, and admission characteris-
tics in Table 3.
Respiratory infections were the most common reason
for admission, forming one-third of admission diagnoses
(see Additional file 1: Table S2). Beta-adrenergic inhal-
ants, antipyretics, and penicillins and other beta-lactam
antibiotics were the most common drugs to which chil-
dren were exposed prior to their admission (see Add-
itional file 1: Table S3), although one in five folders did
not contain a pre-admission drug exposure history. The
same drug classes, together with vitamin and mineral
supplements, were also the most commonly used drugs
during admissions (see Additional file 1: Table S4).
There were 29/1050 (2.8%) HIV-infected children: 24
were on ART before the admission, while five were
newly diagnosed during the index admission and re-
ferred to start ART after discharge. Most (19/24, 79%)
were on a regimen of ritonavir-boosted lopinavir and
two nucleoside reverse transcriptase inhibitors (NRTIs),
while 4/24 (17%) were on a regimen of a non-nucleoside
reverse transcriptase inhibitor and two NRTIs, and 1/24
(4.2%) on an unknown regimen. The NRTIs in use were
lamivudine in all 23 children, abacavir in 18, zidovudine
in 4, and stavudine in 1. Fifty-one children were exposed
to nevirapine for the prevention of mother-to-child HIV
transmission (PMTCT) before and/or during their ad-
missions, with additional zidovudine in 12 children.
Serious ADRs
The multidisciplinary panel confirmed the diagnosis of
160 ADRs, 40 of which were serious (18 caused admis-
sion, 14 prolonged admission, 7 were near-fatal, and one
resulted in death). Twenty serious ADRs were present at
the time of admission (see Additional file 1: Table S5),
and 20 occurred during admission (see Additional file 1:
Table S6). The crude prevalence of serious ADRs was
3.8 per 100 drug-exposed admissions, consisting of 2.7
serious ADRs present at admission per 100 drug-
exposed admissions and 1.9 serious ADRs occurring
during the admission per 100 drug-exposed admissions.
Alternative ways of expressing the ADR prevalence are
given in the supplement (see Additional file 1: Table S7).
Thirty of 40 serious ADRs were classified as type A re-
actions; causality assessment rated seven type A ADRs
as certain, six as probable, and 17 as possible. Ten of 40
serious ADRs were classified as type B reactions or were
classified as a mixture of type A and B mechanisms.
There were 17 drug-ADR pairs implicated in these ten
ADRs, and causality assessment rated 2 pairs as certain,
5 as probable, and 10 as possible.
Serious ADR manifestations encountered more than once
were: four cases of diarrhoea prolonging the admission, two
cases of near-fatal respiratory depression, two cases of near-
fatal hyperkalaemia, two cases of dystonia causing admis-
sion, two cases of urticaria causing admission, and two
cases of bicytopaenia prolonging the admission.
Individual drugs most commonly implicated in serious
ADRs were: prednisone (H02AB07, 5 times), methyl-
prednisolone (H02AB04, 3 times), amoxicillin (J01CA04,
3 times), mycophenolic acid (L04AA06, 3 times), and ta-
crolimus (L04AD02, 3 times). Drug classes most com-
monly implicated in serious ADRs were (by second-level
ATC code): systemic antibacterials (J01) in 12 serious
ADRs, systemic corticosteroids (H02) in 6 serious ADRs,
psycholeptics (N05) in 4 serious ADRs, immunosuppres-
sants (L04) in 4 serious ADRs, direct-acting antivirals
(J05) in 4 serious ADRs, and analgesics (N02) in 3 ser-
ious ADRs (Table 4). Relative to the frequency of expos-
ure to these drug classes, immunosuppressants (L04)
were disproportionately frequently implicated (see Add-
itional file 1: Figure S1).
Five of 30 (17%) type A serious ADRs and 4/17 (24%)
type B serious ADR drug-event pairs were preventable;
in total, 9/40 (23%) serious ADRs had at least one pre-
ventability factor present. The most common prevent-
ability factor was an inappropriate drug choice, which
occurred in 6/40 (15%) serious ADRs. A wide variety of
drugs were considered inappropriate in these cases, in-
cluding benzathine benzylpenicillin, flucloxacillin, ceftri-
axone, ferrous gluconate, clozapine, and amitriptyline.
Inappropriate dose or route of administration occurred
in 2/40 (5%) serious ADRs (drugs involved were vanco-
mycin and metoclopramide), problems with patient ad-
herence occurred in 2/40 (5%) serious ADRs (drugs
involved were flucloxacillin and amitriptyline), insuffi-
cient laboratory monitoring occurred in 1/40 (2.5%) ser-
ious ADR attributed to tacrolimus, and a raised drug
concentration occurred in 1/40 (2.5%) serious ADR at-
tributed to tacrolimus. Alternative ways of reporting the
proportion considered preventable are presented in the
supplement (see Additional file 1: Table S8).
Among the 36 children with serious ADRs, one death
occurred, and this was considered to be directly caused
by an ADR which was the result of an error: benzathine
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benzylpenicillin (instead of benzylpenicillin sodium) was
administered intravenously to a preterm neonate, result-
ing in fatal respiratory arrest. Six children with serious
ADRs remained in hospital at the end of our observation
period, while 29 were discharged or transferred out. The
median (IQR) length of stay observed among children
with serious ADRs was 6 [3–12] days. Six serious ADRs
present at the time of admission were managed entirely
in the short-stay ward: two children with urticaria, two
children with dystonia, and one child each with lower
respiratory tract infection and convulsion. Five serious
ADRs occurring during the hospitalisation prolonged
the hospital stay, yet the affected children were still only
managed in the short-stay ward, including three children
with antibiotic-associated diarrhoea, and one child each
with rash and raised transaminases.
No serious ADRs occurred among term neonates. For
the multivariate logistic regression analysis, we therefore
grouped term neonates together with infants. The logis-
tic regression model (Table 5) confirmed the following
Table 2 Patient characteristics (n = 1050) at first admission to two children’s hospitals, South Africa, 2015
All patients (n = 1050) Patients with ADR(s) (any seriousness) (n = 119) Patients without ADR(s) (n = 931) P-value
Age
Median (IQR) months 11 (2 to 41) 20 (5 to 68) 10 (2 to 37) P = 0.0010e
Age categoriesa
Preterm neonates 32 (3.1%)b, c 6 (5.0%) 26 (2.8%) P = 0.002f
Term neonates 96 (9.1%)c 2 (1.7%) 94 (10%)
Infants 421 (40%) 42 (35%) 379 (41%)
Toddlers 139 (13%) 13 (11%) 126 (14%)
Early childhood 198 (19%) 30 (25%) 168 (18%)
Middle childhood 123 (12%) 18 (15%) 105 (11%)
Early adolescence 41 (3.9%) 8 (6.7%) 33 (3.5%)
Weight-for-age z-score mean (SD)
Infants −1.3 (2.0) (n = 418) −2.4 (2.2) (n = 42) −1.2 (2.0) (n = 376) P = 0.0002g
Toddlers −0.45 (1.5) (n = 137) −0.78 (1.2) (n = 13) −0.41 (1.5) (n = 124) P = 0.3870g
Early childhood −0.54 (1.6) (n = 165) −0.54 (1.7) (n = 24) − 0.54 (1.5) (n = 141) P = 0.9969g
Sex
Male 590 (56%) 69 (58%) 521 (56%) P = 0.676h
Female 460 (44%) 50 (42%) 410 (44%)
HIV infection / exposure status
HIV negative 887 (84%) 91 (76%) 796 (86%) P = 0.003f
HIV indeterminate 134 (13%) 19 (16%) 115 (12%)
HIV infected 29 (2.8%)d 9 (7.6%) 20 (2.1%)
Number of admissions
One 1001 (95%) 109 (92%) 892 (96%) P = 0.134f
Two 43 (4.1%) 9 (7.6%) 34 (3.7%)
Three 5 (0.48%) 1 (0.84%) 4 (0.43%)
Four 1 (0.10%) 0 (0%) 1 (0.11%)
aPreterm neonate, born before 37 completed weeks’ gestation; term neonate, from birth to 27 days; infancy, 28 days to 12 months; toddler, 13 months to 24
months; early childhood, 25 months to 5 years; middle childhood, 6 years to 11 years; early adolescence, 12 years to 18 years
bPreterm neonates included 16/32 (50%) moderate to late preterm (32 to < 37 weeks’ gestation), 12/32 (38%) very preterm (28 to < 32 weeks’ gestation), and 4/32
(13%) extremely preterm (< 28 weeks’ gestation) neonates
cAmong all neonates (n = 128): 93/128 (73%) normal or high birth weight (≥2500 g), 18/128 (14%) low birth weight (1500 to 2499 g), 11/128 (8.6%) very low birth
weight (1000 to 1499 g), and 6/128 (4.7%) extremely low birth weight (≤999 g)
dOf whom 5/29 (17%) not yet on ART, and 24/29 (83%) on ART before and during admission. ART regimens were: 15/24 (63%) on abacavir (ABC) + lamivudine
(3TC) + ritonavir-boosted lopinavir (LPV/r), 3/24 (13%) on ABC + 3TC + efavirenz (EFV), 2/24 (8.3%) on zidovudine (AZT) + 3TC + LPV/r, 1/24 (4.2%) on stavudine





ADR adverse drug reaction; IQR interquartile range; SD standard deviation
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Table 3 Admission characteristics (n = 1106) at two children’s hospitals in South Africa, 2015
All admissions
(n = 1106)
Admissions with ADR(s) (any





RCWMCH 886 (80%) 100 (83%) 786 (80%) P = 0.349c
RMMCH 220 (20%) 20 (17%) 200 (20%)
Type of admission
Acute admission 998 (90%) 113 (94%) 885 (90%) P = 0.124c
Elective admission 108 (9.8%) 7 (5.8%) 101 (10%)
Admission ward
Short-stay ward only 514 (46%) 28 (23%) 486 (49%) P < 0.001c
Medical wards, not ICUa 459 (42%) 60 (50%) 399 (40%)
Any time spent in ICU 133 (12%) 32 (27%) 101 (10%)
Duration of stay observed (censored at study end) (n = 1105)b
1 day 72 (6.5%) 2 (1.7%) 70 (7.1%) P < 0.001c
2 to 3 days 541 (49%) 27 (23%) 514 (52%)
4 to 6 days 229 (21%) 20 (17%) 209 (21%)
≥ 7 days 263 (24%) 71 (59%) 192 (19%)
Median (days) 3 8 3 P < 0.0001e
Interquartile range (days) 2 to 6 4 to 13 2 to 5
Range (days) 1 to 34 1 to 34 1 to 34
Total stay observed (patient-days) 5744 1198 4546
Type of exit (n = 1105)b
Discharged / transferred out 1038 (94%) 100 (83%) 938 (95%) P < 0.001d
Died 13 (1.2%) 2 (1.7%) 11 (1.1%)
Censored (remained in-hospital by end of ob-
servation period)
54 (4.9%) 18 (15%) 36 (3.7%)
Drug exposure over 30-day period before admission
No drug history documented in folder 226 (20%) 12 (10%) 214 (22%) P < 0.001c
No drugs 130 (12%) 7 (5.8%) 123 (12%)
Had ≥1 drug(s) 750 (68%) 101 (84%) 649 (66%)
Median background drug count 2 (n = 880) 4 (n = 108) 2 (n = 772) P < 0.0001e
Interquartile range 1 to 4 2 to 7 1 to 4
Range 0 to 47 0 to 42 0 to 47
Drug exposure during admission (n = 1105)b
No drugs 69 (6.2%) 2 (1.7%) 67 (6.8%) P = 0.028c
Had ≥1 drug(s) 1036 (94%) 118 (98%) 918 (93%)
Median in-hospital drug count 4 (n = 1105) 11 (n = 120) 4 (n = 985) P < 0.0001e
Interquartile range 3 to 9 7 to 19 2 to 7
Range 0 to 46 0 to 46 0 to 36
Median daily drug count 5 (n = 5744
patient-days)
9 (n = 1198 patient-days) 4 (n = 4546 patient-days) P < 0.0001e
Interquartile range 3 to 8 5 to 13 2 to 7
Range 0 to 29 0 to 29 0 to 23
Total drug exposure (before and during admission)
No drugs 49 (4.4%) 0 (0%) 49 (5.0%) P = 0.012c
Had ≥1 drug(s) 1057 (96%) 120 (100%) 937 (95%)
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independent associations with serious ADRs: preterm
neonates, adjusted odds ratio (aOR) with 95% CI 5.97
(1.30 to 27.3) versus referent category of infants and
term neonates; middle childhood, aOR 3.63 (1.24 to
10.6) versus infants and term neonates; HIV-infection,
aOR 3.87 (1.14 to 13.2) versus HIV-negative; and
increasing drug count, aOR 1.08 (1.04 to 1.12) per
additional drug.
In an exploratory logistic regression model (see Add-
itional file 1: Table S9) weight-for-age z-score was not as-
sociated with serious ADR occurrence after adjustment
for age, sex, hospital, HIV category, and drug count.
Four of 29 (13.8%) HIV-infected children in our survey
experienced a serious ADR, including two who were ad-
mitted with serious ADRs present at the time of admis-
sion and another two who experienced serious ADRs
Table 3 Admission characteristics (n = 1106) at two children’s hospitals in South Africa, 2015 (Continued)
All admissions
(n = 1106)
Admissions with ADR(s) (any




Median total drug count 6 12 5 P < 0.0001e
Interquartile range 3 to 10 8 to 21 3 to 9
Range 0 to 52 2 to 47 0 to 52
aMay have moved from short-stay to medical ward; may have included a high-care stay during the admission




ADR adverse drug reaction; ICU intensive care unit; RCWMCH Red Cross War Memorial Children’s Hospital; RMMCH Rahima Moosa Mother and Child Hospital
Table 4 Drug classes commonly implicated in serious ADRs and the associated ADR manifestations
Drug class Serious ADRs
Systemic antibacterials (J01), implicated in 12 serious
ADRs
• Diarrhoea with amoxicillin (2 cases) and with clarithromycin (1 case), prolonging the
admissions
• Urticaria with phenoxymethylpenicillin (1 case) and with ceftriaxone (1 case), causing the
admissions
• Maculo-papular rash with flucloxacillin, prolonging the admission
• Respiratory arrest with intravenous benzathine benzylpenicillin (medication error), fatal
• Red-man syndrome with vancomycin, near-fatal
• Thrombocytopaenia with amoxicillin, causing the admission
• Agranulocytosis with co-trimoxazole (and zidovudine), causing the admission
• Bicytopaenia with ceftriaxone, co-trimoxazole (and ganciclovir), prolonging the admission
• Metabolic acidosis with amikacin (and paracetamol), causing the admission
Systemic corticosteroids (H02), implicated in 6 serious
ADRs
• Lower respiratory tract infection with prednisone, causing the admission
• Upper respiratory tract infection with prednisone, causing the admission
• Pneumocystis jirovecii pneumonia with prednisone and methylprednisolone, prolonging the
admission
• Salmonellosis with prednisone (and mycophenolic acid), prolonging the admission
• Pancreatitis with prednisone and methylprednisolone, prolonging the admission
• Sepsis with methylprednisolone (and mycophenolic acid and tacrolimus), prolonging the
admission
Psycholeptics (N05), implicated in 4 serious ADRs • Respiratory depression with chlorpromazine, lorazepam and diazepam (and phenobarbital),
near-fatal
• Respiratory depression with diazepam (and morphine and phenobarbital), near-fatal
• Apnoea with midazolam, near-fatal
• Delirium with clozapine, causing the admission
Immunosuppressants (L04), implicated in 4 serious
ADRs
• Macrocytic anaemia with mycophenolic acid and tacrolimus, causing the admission
• Neutropaenic sepsis with tacrolimus, prolonging the admission
• Sepsis with mycophenolic acid and tacrolimus (and methylprednisolone), prolonging the
admission
• Salmonellosis with mycophenolic acid (and prednisone), prolonging the admission
Direct-acting antivirals (J05), implicated in 4 serious
ADRs
• Agranulocytosis with zidovudine (and co-trimoxazole), causing the admission
• Diarrhoea with lopinavir-ritonavir, prolonging the admission
• Increased transaminases with efavirenz, prolonging the admission
• Bicytopaenia with ganciclovir (and ceftriaxone and co-trimoxazole), prolonging the
admission
Analgesics (N02), implicated in 3 serious ADRs • Respiratory depression with morphine (and diazepam and phenobarbital), near-fatal
• Metabolic acidosis with paracetamol (and amikacin), causing the admission
• Increased paracetamol plasma concentration, prolonging the admission
ADR adverse drug reaction
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during their admission. In three of the four cases, anti-
retroviral agents were implicated in the ADRs. None of
the serious ADRs in HIV-infected children was consid-
ered preventable. The use of PMTCT was not implicated
in any serious ADRs.
Non-serious ADRs
We found a further 120 non-serious ADRs, which we
describe in the supplement. These included 26 non-
serious ADRs present at the time of admission (see Add-
itional file 1: Table S10) and 94 non-serious ADRs oc-
curring during the admission (see Additional file 1:
Table S11). The most commonly implicated drug classes
implicated in non-serious ADRs were systemic antibac-
terials (J01) in 48 ADRs, drugs for obstructive airway
diseases (R03) in 23 ADRs, diuretics (C03) in 17 ADRs,
mineral supplements (A12) in 11 ADRs, and systemic
corticosteroids (H02) in 10 ADRs (see Additional file 1:
Table S12).
Discussion
In two South African children’s hospitals we found that
3.8 serious ADRs occurred per 100 drug-exposed admis-
sions. Serious ADRs were associated with increasing
drug exposure, HIV infection, and two age categories –
premature neonates and middle childhood. A wide range
of ADR manifestations occurred, and commonly impli-
cated drug classes included antimicrobials, systemic cor-
ticosteroids, and antiviral agents. Considering that one
in five serious ADRs was fatal or near-fatal, and about
one in five serious ADRs was also preventable, these
findings have significant public health importance.
It is difficult to compare the prevalence of ADRs
across studies, due to differences in study settings and
study designs. Nevertheless, a comprehensive 2012 sys-
tematic review [4] estimated the proportion of paediatric
admissions caused by ADRs to be 2.9% (95% CI 2.6 to
3.1%), using a denominator of all admissions and not
only drug-exposed admissions. In our survey 1.8% of ad-
missions were due to an ADR. However, our survey ex-
cluded admissions to the oncology ward, whereas the
2012 systematic review’s figure is significantly influenced
by two large surveys which found ADR-related admis-
sions to oncology wards to be common [17, 18]. Pub-
lished subsequent to the 2012 systematic review [4],
surveys from paediatric settings in sub-Saharan Africa
suggested the proportion of admissions due to ADRs to
be 5.7% (16/282) in Cape Town, South Africa [19], 4.7%
Table 5 Multivariate logistic regression model of factors associated with serious ADR (n = 1001 first admissions with documented
exposure to ≥1 drug(s))
n Bivariate analysis Multivariate analysis
Unadjusted OR (95% CI) P Adjusteda OR (95% CI) P
Age categoryb
Preterm neonate 31 5.14 (1.34 to 19.7) 0.017 5.97 (1.30 to 27.3) 0.021
Term neonate & Infant 490 Referent
Toddler 137 1.07 (0.292 to 3.96) 0.914 1.13 (0.295 to 4.33) 0.858
Early childhood 188 1.58 (0.567 to 4.42) 0.381 1.61 (0.521 to 4.97) 0.408
Middle childhood 114 3.62 (1.40 to 9.40) 0.008 3.63 (1.24 to 10.6) 0.018
Early adolescent 41 3.79 (1.00 to 14.4) 0.050 2.88 (0.667 to 12.5) 0.156
Sex
Male 564 Referent
Female 437 1.08 (0.537 to 2.16) 0.832 0.894 (0.428 to 1.87) 0.766
Hospital
RXWMCH 812 Referent
RMMCH 189 0.953 (0.388 to 2.34) 0.917 0.938 (0.324 to 2.71) 0.906
HIV category
Negative 840 Referent
Infected 29 5.44 (1.76 to 16.9) 0.003 3.87 (1.14 to 13.2) 0.031
Indeterminate 132 1.34 (0.502 to 3.57) 0.560 1.59 (0.502 to 5.05) 0.429
Total drug count
Per additional drug 1001 1.09 (1.05 to 1.13) < 0.001 1.08 (1.04 to 1.12) < 0.001
aAdjusted for other variables in the model
bPreterm neonate, born before 37 completed weeks’ gestation; term neonate, from birth to 27 days; infancy, 28 days to 12months; toddler, 13 months to 24
months; early childhood, 25 months to 5 years; middle childhood, 6 years to 11 years; early adolescence, 12 years to 18 years
ADR adverse drug reaction; OR odds ratio; RCWMCH Red Cross War Memorial Children’s Hospital; RMMCH Rahima Moosa Mother and Child Hospital
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(114/2433) in Eritrea [20], and 0.60% (12/2004) in Lagos,
Nigeria [21]. A study from Jimma, Ethiopia, with paedi-
atric adverse drug events as outcome (i.e., a slightly dif-
ferent outcome than ADRs), determined the proportion
of admissions to be adverse drug event-related as 0.63%
(4/634) [22]. The prevalence of serious ADRs during
paediatric admissions was not studied in the 2012 sys-
tematic review, although the prevalence of all in-hospital
ADRs (i.e., of any seriousness) ranged from 0.6 to 16.8%
among included studies [4]. An earlier systematic review
found that 7 to 20% of in-hospital paediatric ADRs were
serious [23], with our study’s proportion (20/114, 18%)
falling within this range. A previous study from Nigeria
found that 0.29% (11/3821) of retrospectively reviewed
paediatric admissions were prolonged due to serious
ADRs [24]. Our methodology, involving prospective re-
view, probably explains why we found a much higher
proportion of admissions (1.8%) being affected by ser-
ious ADRs occurring during the admission. Taking all
these factors in consideration, our interpretation is that
serious ADRs probably occurred at a similar frequency
in our hospitals as in other paediatric settings in sub-
Saharan Africa and elsewhere.
There is robust evidence from previous adult and
paediatric systematic reviews [4, 23, 25] confirming the
association between ADR occurrence and increasing
drug count. Although an association between serious
ADR occurrence and sex was found in the majority of
studies included in the 2012 paediatric systematic review
[4], we did not find any such association in this survey.
Regarding associations with age, the association between
ADR occurrence and prematurity which is attributable
to reduced drug metabolism and clearance is also well
established [26]. Previous hospital-based surveys in the
United Kingdom [18, 27], United States [17], and in sub-
Saharan Africa [20] have also, similar to our finding, de-
scribed an association between ADR occurrence and
later childhood. This association has been explained by
older children’s ability to communicate their ADRs bet-
ter than younger children [27]. Another explanation
could be that older children tend to be admitted for
chronic disease processes requiring chronic medications
with a greater exposure-time within which ADRs might
occur, whereas younger children are mostly admitted for
acute infectious disease processes requiring short-term
treatment. HIV infection causes chronic immune stimu-
lation, increased oxidative stress, and altered patterns of
drug metabolism [28], which may explain our finding
that HIV infection was independently associated with
the occurrence of serious ADRs. Our group has previ-
ously shown the same independent association between
HIV infection and serious ADRs in South African adults
[10, 29], and an association between HIV infection and
serious ADRs was also found in a recent paediatric
survey from another Cape Town hospital [19]. Lastly,
despite our unadjusted analysis suggesting an association
between serious ADR occurrence and low weight-for-
age, no such association was found after adjustment for
other factors.
In the 2012 systematic review, between 7 and 98% of
ADRs were reportedly preventable [4]. Our proportion
of serious ADRs considered preventable, i.e. 23%, is con-
siderably lower than the findings in our adult serious
ADR surveys, where 43 to 45% of ADRs were considered
preventable [10, 29], but is in keeping with proportions
from Nigeria (20%) [21] and Ethiopia (33%) [22]. The
most common reason why serious ADRs were consid-
ered preventable in this survey was an inappropriate
choice of drug (15%), which was also the most common
reason in our adult surveys [10, 29] and one of the most
common reasons (23%) cited in the 2012 systematic re-
view [4]. Our survey did not yield a clear pattern of spe-
cific drugs considered inappropriate, with six different
drugs involved in the six serious ADRs considered pre-
ventable for this reason.
In our survey, one child died due to an ADR, and this
ADR was related to a medication error. Medication er-
rors are common in sub-Saharan African hospitals: 75%
of children admitted to general paediatric wards in a
South African [30] and an Ethiopian [31] hospital were
exposed to medication errors, as were 95% of children
admitted to a South African paediatric intensive care
unit [32]. High mortality and an association with medi-
cation error was also seen in the Ethiopian adverse drug
event survey [22], where 9% of adverse drug events re-
sulted in permanent harm or death, with three of the
four events that resulted in permanent harm in that sur-
vey being due to medication error. Higher mortality
rates than ours occurred in Eritrea, where 19/114 (17%)
children admitted for ADRs died due to their ADRs [20],
and in Nigeria, where 2/12 (17%) of children admitted
for ADRs died due to their ADRs [21]. While our fatality
rate may seem reassuringly low against these sub-
Saharan African studies, it should be noted that an add-
itional seven ADRs in our survey were considered near-
fatal, meaning that 20% of serious ADRs may potentially
have resulted in children’s deaths.
The drug classes most commonly implicated in serious
ADRs in our survey were systemic antibacterials, sys-
temic corticosteroids, antivirals, psycholeptics, immuno-
suppressants, and analgesics. These mostly correspond
with the findings of the 2012 systematic review [4], bear-
ing in mind we did not survey oncology wards and thus
did not observe ADRs attributable to cytotoxics. Anti-
bacterial agents were also commonly implicated in other
sub-Saharan African surveys [19, 21, 22], particularly in
association with rashes [21]. Significantly, our list of
commonly implicated drugs includes antivirals, which
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was not a common cause of ADRs in the 2012 system-
atic review [4], and which, among three sub-Saharan Af-
rican studies [19, 21, 22] was only mentioned as a
commonly implicated class of drugs in one [19].
Despite choosing sites with large paediatric ART
clinics, where we expected to find admissions of HIV-
infected children to be concentrated, our survey in-
cluded a relatively low number of HIV-infected children
among those admitted. We interpret this as evidence of
the efficacy of PMTCT, which has resulted in decreasing
paediatric HIV incidence and prevalence [2], and of the
generally high efficacy and low toxicity associated with
current paediatric antiretroviral regimens in use. Never-
theless, among the small number of HIV-infected chil-
dren admitted during our survey, a high proportion (9/
29, 31%) had ADRs, which is comparable to another
South African survey in which 9/21 (43%) HIV-infected
children admitted to hospital had ADRs [19]. Our survey
included 4/29 (14%) HIV-infected children with serious
ADRs, of which three were attributed to the use of ART,
illustrating the importance of continued vigilance when
using these drugs.
One limitation of our study is that we have likely
under-estimated ADR prevalence at the time of admis-
sion, as one in five folders were missing pre-admission
drug exposure history, and we did not interview patients
or caregivers to complement information not docu-
mented in clinical notes or verify the accuracy of re-
corded drug histories. Our choice of study wards (i.e.,
excluding surgical and oncology wards) also resulted in
under-ascertainment of ADRs associated with the use of
anaesthetic and cytotoxic agents, which were major
drivers of serious ADRs elsewhere [17, 18, 27]. On the
other hand, our study was strengthened by the inclusion
of patients admitted to the short-stay ward, a setting that
is often excluded [17–19, 22] from ADR surveys. We
found that one quarter of all serious ADRs occurred in
the short-stay ward and would have been missed had we
not surveyed patients admitted there. Our study’s repre-
sentativeness was also strengthened by reviewing some,
although admittedly not all, neonatal admissions, and by
reviewing admissions to the intensive care unit.
A strength of our study was the development of a
localised trigger tool to assist in identifying potential
ADRs.
We did not determine the contribution of off-label use
of drugs to the burden of ADRs. This was previously de-
scribed as a risk factor for development of ADRs: in the
2012 systematic review [4] three out of three studies
which investigated it confirmed unlicensed or off-label
use to be a risk factor for the occurrence of ADRs.
Our study was conducted in specific wards of two
urban hospitals in the two best-resourced provinces of
South Africa, and findings may therefore be considered
context-specific, rather than generalisable to other set-
tings. For this reason, replicating this survey in other
wards, or in more resource-constrained or rurally lo-
cated hospitals, and/or periodically repeating this survey
or a scaled version thereof would provide a clearer pic-
ture of the burden of serious adverse drug reactions our
children face.
Conclusions
Serious ADR prevalence at two paediatric hospitals in
South Africa was, at 3.8 serious ADRs per 100 drug-
exposed admissions, similar to the prevalence described
in hospital settings elsewhere. Similar to other sub-
Saharan African studies, a large proportion of serious
ADRs were fatal or near-fatal, and around one-fifth of
serious ADRs were preventable. In keeping with South
Africa’s high burden of HIV, we found that the antiviral
drug class was one of the most commonly implicated
classes in serious ADRs. Serious ADRs were independ-
ently associated with increasing drug count, HIV-
infection, and two age categories: premature neonates
and middle childhood.
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